



(51) International Patent Classification:

C07D 401/14 (2006.01) A61K 31/506 (2006.01)
 A61K 31/427 (2006.01) C07D 401/04 (2006.01)
 A61K 31/433 (2006.01) C07D 417/04 (2006.01)
 A61K 31/444 (2006.01) C07D 417/14 (2006.01)
 A61K 31/497 (2006.01)

(21) International Application Number:

PCT/EP2015/055629

(22) International Filing Date:

18 March 2015 (18.03.2015)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/968,172 20 March 2014 (20.03.2014) US
 14185274.9 18 September 2014 (18.09.2014) EP

(71) Applicant: BAYER PHARMA AKTIENGESELLSCHAFT [DE/DE]; Müllerstr. 178, 13353 Berlin (DE).

(72) Inventors: THEDE, Kai; Stargarder Straße 62, 10437 Berlin (DE). BENDER, Eckhard; Gudrunstr. 6, Wohnung 9, 40764 Langenfeld (DE). SCOTT, William; 210 Saddle Hill Drive, Guilford, Connecticut 06437 (US). RICHTER, Anja; Schützenstraße 18, 12105 Berlin (DE). ZORN, Ludwig; Osianderweg 45a, Berlin 13509 (DE). LIU, Ningshu; Ringstr 89a, 12203 Berlin (DE). MÖNNING, Ursula; Eichendamm 5, 15569 Woltersdorf (DE). SIEGEL, Franziska; Pappelallee 58, 10437 Berlin (DE). GOLZ, Stefan; Sperlingstrasse 17, 45472 Mülheim an der Ruhr (DE). HÄGEBARTH, Andrea; An den Eldenaer Höfen 13, 10247 Berlin (DE). LIENAU, Philip; Jahnstr. 13, 10967 Berlin (DE). PUEHLER, Florian; 28 Croton St, Wellesley, Massachusetts 02481 (US). BASTING, Daniel; Düsseldorf Str. 127, 51063 Köln (DE). SCHNEIDER, Dirk; Bodelschwingweg 39, 42115 Wuppertal (DE). MÖWES, Manfred; Maßmannstr. 9, 12163

Berlin (DE). GEISLER, Jens; Merianweg 10, 13587 Berlin (DE).

(74) Agent: BIP PATENTS; c/o Bayer Intellectual Property GmbH, Alfred-Nobel-Str. 10, 40789 Monheim am Rhein (DE).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))

Published:

— with international search report (Art. 21(3))
 — before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

(54) Title: NOVEL COMPOUNDS

(57) Abstract: The present invention relates to inhibitors of the Wnt signalling pathways of general formula (I) as described and defined herein, to methods of preparing said compounds, to intermediate compounds useful for preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative disorder, as a sole agent or in combination with other active ingredients.

